154 related articles for article (PubMed ID: 31802629)
1. Metabolomic profiling in neuroblastoma.
Quintás G; Yáñez Y; Gargallo P; Juan Ribelles A; Cañete A; Castel V; Segura V
Pediatr Blood Cancer; 2020 Mar; 67(3):e28113. PubMed ID: 31802629
[TBL] [Abstract][Full Text] [Related]
2. A Pilot Study on the Utility of Serum Metabolomics in Neuroblastoma Patients and Xenograft Models.
Beaudry P; Campbell M; Dang NH; Wen J; Blote K; Weljie AM
Pediatr Blood Cancer; 2016 Feb; 63(2):214-20. PubMed ID: 26481088
[TBL] [Abstract][Full Text] [Related]
3. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples.
De Preter K; Mestdagh P; Vermeulen J; Zeka F; Naranjo A; Bray I; Castel V; Chen C; Drozynska E; Eggert A; Hogarty MD; Izycka-Swieszewska E; London WB; Noguera R; Piqueras M; Bryan K; Schowe B; van Sluis P; Molenaar JJ; Schramm A; Schulte JH; Stallings RL; Versteeg R; Laureys G; Van Roy N; Speleman F; Vandesompele J
Clin Cancer Res; 2011 Dec; 17(24):7684-92. PubMed ID: 22031095
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic pattern of childhood neuroblastoma obtained by ¹H-high-resolution magic angle spinning (HRMAS) NMR spectroscopy.
Imperiale A; Elbayed K; Moussallieh FM; Neuville A; Piotto M; Bellocq JP; Lutz P; Namer IJ
Pediatr Blood Cancer; 2011 Jan; 56(1):24-34. PubMed ID: 20949594
[TBL] [Abstract][Full Text] [Related]
5. Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome.
Cornero A; Acquaviva M; Fardin P; Versteeg R; Schramm A; Eva A; Bosco MC; Blengio F; Barzaghi S; Varesio L
BMC Bioinformatics; 2012 Mar; 13 Suppl 4(Suppl 4):S13. PubMed ID: 22536959
[TBL] [Abstract][Full Text] [Related]
6. The role of β-catenin and paired-like homeobox 2B (PHOX2B) expression in neuroblastoma patients; predictive and prognostic value.
El-Shazly SS; Hassan NM; Abdellateif MS; El Taweel MA; Abd-Elwahab N; Ebeid EN
Exp Mol Pathol; 2019 Oct; 110():104272. PubMed ID: 31220430
[TBL] [Abstract][Full Text] [Related]
7. A 3-Protein Expression Signature of Neuroblastoma for Outcome Prediction.
Xie Y; Xu H; Fang F; Li Z; Zhou H; Pan J; Guo W; Zhu X; Wang J; Wu Y
Am J Surg Pathol; 2018 Aug; 42(8):1027-1035. PubMed ID: 29794872
[TBL] [Abstract][Full Text] [Related]
8. Artificial neural network classifier predicts neuroblastoma patients' outcome.
Cangelosi D; Pelassa S; Morini M; Conte M; Bosco MC; Eva A; Sementa AR; Varesio L
BMC Bioinformatics; 2016 Nov; 17(Suppl 12):347. PubMed ID: 28185577
[TBL] [Abstract][Full Text] [Related]
9. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
10. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma.
Popov A; Druy A; Shorikov E; Verzhbitskaya T; Solodovnikov A; Saveliev L; Tytgat GAM; Tsaur G; Fechina L
J Cancer Res Clin Oncol; 2019 Feb; 145(2):535-542. PubMed ID: 30603901
[TBL] [Abstract][Full Text] [Related]
12. A quantitative multimodal metabolomic assay for colorectal cancer.
Farshidfar F; Kopciuk KA; Hilsden R; McGregor SE; Mazurak VC; Buie WD; MacLean A; Vogel HJ; Bathe OF
BMC Cancer; 2018 Jan; 18(1):26. PubMed ID: 29301511
[TBL] [Abstract][Full Text] [Related]
13. Untargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma.
Barco S; Lavarello C; Cangelosi D; Morini M; Eva A; Oneto L; Uva P; Tripodi G; Garaventa A; Conte M; Petretto A; Cangemi G
Front Oncol; 2022; 12():845936. PubMed ID: 35756625
[TBL] [Abstract][Full Text] [Related]
14. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
15. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
[TBL] [Abstract][Full Text] [Related]
16. Synaptic Vesicle Protein 2 and Vesicular Monoamine Transporter 1 and 2 Are Expressed in Neuroblastoma.
Georgantzi K; Tsolakis AV; Jakobson Å; Christofferson R; Janson ET; Grimelius L
Endocr Pathol; 2019 Sep; 30(3):173-179. PubMed ID: 31317476
[TBL] [Abstract][Full Text] [Related]
17. Calreticulin expression in neuroblastoma--a novel independent prognostic factor.
Hsu WM; Hsieh FJ; Jeng YM; Kuo ML; Chen CN; Lai DM; Hsieh LJ; Wang BT; Tsao PN; Lee H; Lin MT; Lai HS; Chen WJ
Ann Oncol; 2005 Feb; 16(2):314-21. PubMed ID: 15668290
[TBL] [Abstract][Full Text] [Related]
18. DUSP5 expression associates with poor prognosis in human neuroblastoma.
Aurtenetxe O; Zaldumbide L; Erramuzpe A; López R; López JI; Cortés JM; Pulido R; Nunes-Xavier CE
Exp Mol Pathol; 2018 Dec; 105(3):272-278. PubMed ID: 30171833
[TBL] [Abstract][Full Text] [Related]
19. Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma.
Galli S; Naranjo A; Van Ryn C; Tilan JU; Trinh E; Yang C; Tsuei J; Hong SH; Wang H; Izycka-Swieszewska E; Lee YC; Rodriguez OC; Albanese C; Kitlinska J
Am J Pathol; 2016 Nov; 186(11):3040-3053. PubMed ID: 27743558
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
